A new patent application for using VAR2CSA in combination with novel linkers and toxins for treating solid tumors has been issued in Great Britain, Germany, France, Belgium, Ireland and Switzerland. This new approval adds to the rapidly growing VAR2 Pharma patent portfolio on novel cancer treatment technologies.

.